Associated tags: Research, Clinical data management, ChromeOS, Patient, Clinical trial, Pharmaceutical industry
Locations: FLORIDA, MORRISVILLE, MASSACHUSETTS, UNITED KINGDOM, PENNSYLVANIA, LONDON
Retrieved on:
Monday, February 12, 2024
Consensus,
Cognition,
Schizophrenia,
MIS,
Deficit spending,
ChromeOS,
Neurology,
CNS,
Patient,
DSM-IV codes,
Research,
Consensus decision-making,
Partnership BOSTON and LONDON, Feb. 12, 2024 /PRNewswire-PRWeb/ -- uMotif – one of the clinical research technology market's fastest-growing companies – and MoCA Cognition, creators of the leading test for early cognitive impairment detection – are collaborating to make it easier for sponsors and CROs to capture quality cognitive function and eCOA/ePRO data for CNS research.
Key Points:
- The company continues to deepen its portfolio across CNS through its partnership with MoCA Cognition, whose MoCA Test (Montreal Cognitive Assessment) was ranked No.
- MoCA Cognition CEO and Neurologist Dr. Ziad Nasreddine created the MoCA Test in 1996 to help clinicians and researchers rapidly scan multiple cognitive domains and detect impairment.
- The standard MoCA test is administered to patients, and can be uploaded into the uMotif platform for central rating and review.
- Solutions using the standard MoCA test and the uMotif platform are available for immediate deployment.
ASX,
ChromeOS,
Patient,
SCOPE,
Research,
Biostatistics,
American Opportunity Tax Credit,
Partnership,
Industry Dive,
Syneos Health,
Data analysis,
Clinical trial,
Clinical data management,
Motif,
Parkinson's disease,
CNS,
Pharmaceutical industry BOSTON and LONDON, Jan. 22, 2024 /PRNewswire-PRWeb/ -- uMotif – one of the clinical research technology market's fastest-growing companies – continues to move the industry forward with innovations to its modern, patient-centric eCOA/ePRO platform powering clinical trials and real-world studies for an expanding, global customer base.
Key Points:
- Enriched capabilities include an adaptive scheduling and questionnaire engine, a comprehensive patient engagement toolkit, and advanced analytics and custom reporting.
- uMotif and advanced biostatistics consultancy Veramed teamed to redefine how eCOA/ePRO data is collected, reported, visualized, and analyzed.
- SAFIRA Clinical Research independently validated the Motif as the first new data capture innovation since paper instruments on smartphones – eliminating reliance on text-based instruments.
- Meet the uMotif team at SCOPE Summit 2024, Booth 731 to discuss how we can help your organization improve its clinical research programs.
Retrieved on:
Thursday, November 9, 2023
ASX,
Cognitive science,
American Opportunity Tax Credit,
DSM-IV codes,
CNS,
Health,
ChromeOS,
Research,
Cogstate Brief Battery,
Partnership,
Cognition,
Pharmaceutical industry,
Fine chemical BOSTON and LONDON, Nov. 9, 2023 /PRNewswire-PRWeb/ -- uMotif – one of the clinical research technology market's fastest growing companies – announced today a partnership with cognitive science leaders Cogstate Limited (ASX:CGS). The collaboration brings research sponsors and CROs the combined power of uMotif's modern cloud-based, patient-centric eCOA/ePRO platform and Cogstate's market-leading, cognitive testing services for digital assessments and rater training and monitoring.
Key Points:
- Together, we'll significantly improve patient engagement and data quality in all therapeutic areas, and especially CNS research."
- -- uMotif CEO Steve Rosenberg
uMotif and Cogstate will build on existing work together, including a major Phase 2 clinical trial of a psychedelic therapeutic.
- "We are excited to jointly deliver modern technologies and solutions that improve cognitive data insights in the trials we support."
- Together, we'll significantly improve patient engagement and data quality in all therapeutic areas, and especially CNS research."
Retrieved on:
Wednesday, September 20, 2023
BOSTON and LONDON, Sept. 20, 2023 /PRNewswire-PRWeb/ -- uMotif – one of the clinical research technology market's fastest growing companies – announced that CEO Steve Rosenberg has once again been voted one of the PharmaVoice 100 most influential and inspiring people in the global healthcare and life sciences industries. (Read Steve's profile here)
Key Points:
- (Read Steve's profile here )
PharmaVoice100 honorees are selected from a pool of nominations submitted by readers and colleagues, and then evaluated by the PharmaVoice team.
- With a career spanning 40+ years in software development, for the past 20 years Steve has guided companies to develop, commercialize and promote technologies that accelerate patient-centric clinical R&D.
- Steve is known for his success in urging the life sciences industry to invest in clinical research technologies to gather vast amounts of high-quality data, to improve the conduct of clinical trials.
- "This industry is a ground-breaking one capable of changing the world through science and technology," said Meagan Parrish, lead editor of PharmaVoice.
Partnership,
Workflow,
American Opportunity Tax Credit,
Clinical trial,
Patient-Centered Outcomes Research Institute,
Human,
Research,
Electronic,
Syneos Health,
Patient,
Medical imaging,
Pharmaceutical industry In addition to uMotif providing eCOA and ePRO services for Syneos Health customers, the companies will develop and deploy an exclusive patient-centric platform to deliver seamless, integrated customer solutions – including patient identification, recruitment, eConsent, eDiary, patient engagement and retention, and payments.
Key Points:
- In addition to uMotif providing eCOA and ePRO services for Syneos Health customers, the companies will develop and deploy an exclusive patient-centric platform to deliver seamless, integrated customer solutions – including patient identification, recruitment, eConsent, eDiary, patient engagement and retention, and payments.
- Complemented by the Company’s StudyKIK recruitment technology platform, Syneos Health will build a single application to help drive better engagement, compliance and retention with patients, and reduce site burden.
- “At Syneos Health, we are constantly evolving our solutions to address unmet customer, site and patient needs.
- The modern platform can be quickly adapted to meet protocol specific requirements, providing optimal flexibility for sponsors, sites and patients.
Volume Ten,
University,
White British,
Arthritis,
Culture,
Journal of Dermatological Science,
Department of Computer Science, University of Manchester,
Research fellow,
Research,
Manchester Digital,
Black,
Attitude,
Embarrassment,
Assistant,
Cross,
Pain,
Family medicine,
International Journal of Population Data Science,
Erasmus MC,
Patient,
Division,
Senior lecturer,
Frustration,
Pain management,
Chronic pain,
Human musculoskeletal system,
Our World in Data,
White,
JMIR,
Birth control,
Informatics BOSTON and LONDON, May 31, 2023 /PRNewswire-PRWeb/ -- How people identify and report pain varies based on ethnicity, according to a University of Manchester study. The study, in collaboration with uMotif, was based on the novel Manchester Digital Pain Manikin self-reporting app which was used by participants to record their pain.
Key Points:
- The study, in collaboration with uMotif , was based on the novel Manchester Digital Pain Manikin self-reporting app which was used by participants to record their pain.
- Chronic pain, which affects approximately 28 million people in the UK alone, can create a personal and economic burden.
- It is essential to accurately measure pain, know its causes, and estimate its impact on people's lives.
- uMotif Co-founder and Chief Design Officer Ben James ( LinkedIn ) said, "It was an honor for the Digital Pain Manikin app to be used in such an important study.
Industry Dive,
Clinical data management,
American Opportunity Tax Credit,
ISPOR,
Clinical trial,
ICON,
Innovation,
Research,
Phenome-wide association study,
Organization,
Motif,
Patient,
Poster,
BYOD,
ChromeOS,
Migration,
Pharmaceutical industry,
Medical imaging BOSTON, May 8, 2023 /PRNewswire-PRWeb/ -- uMotif – one of the clinical trial technology market's fastest growing companies – reiterated its status as the pacesetter in next-generation eCOA/ePRO by welcoming SAFIRA Clinical Research Co-founder and international eClinical technology expert Willie Muehlhausen as a Scientific Advisor.
Key Points:
- uMotif CEO Steve Rosenberg ( LinkedIn ) said, "We're delighted to welcome Willie Muehllhausen to uMotif as a Scientific Advisor.
- He co-founded SAFIRA Clinical Research in 2021 to offer services to decentralized clinical trial technology vendors, sponsors and CROs.
- SAFIRA Clinical Research has become the go-to organization for providing unbiased, independent, scientific technology and product evaluations.
- Prior to SAFIRA Clinical Research, Muehlhausen was Founder and Managing Director of Muehlhausen Ltd, where he advised sponsors, vendors, investment companies and researchers on digitization strategies for remote and virtual clinical trials.
Partnership,
ISPOR,
Clinical trial,
Meta-analysis,
Parkinson's disease,
Data analysis,
Patient,
Biostatistics,
Geography,
Pharmaceutical industry,
Veram semper et solidam BOSTON, May 8, 2023 /PRNewswire-PRWeb/ -- uMotif – one of the clinical trial technology market's fastest growing companies – continues to redefine how eCOA/ePRO data is collected, reported, visualized and analyzed with the announcement of a strategic partnership with advanced biostatistics consultancy Veramed.
Key Points:
- The highly-scalable uMotif eCOA/ePRO platform combines the industry's most innovative eCOA/ePRO technology with an unmatched focus on true patient centricity.
- The modern platform consistently achieves greater than 90 percent compliance, generating double the expected volume of data in real-world studies.
- Together, uMotif and Veramed generate high quality, actionable insights to drive quantifiable improvements in clinical research.
- Through the partnership with Veramed, sponsors get the unique advantages of the industry's most advanced data analysis and visualization support on top of uMotif's market-leading platform for ePRO/eCOA data capture, reporting, and analytics.
Retrieved on:
Wednesday, March 15, 2023
Medtech,
Research,
Political science,
Communication,
Transformation,
London Stock Exchange,
IPO,
London,
FTSE,
Biomet,
GM,
Corporation,
Motif,
Quality,
Rutgers University,
Health,
General counsel,
Convatec,
Integration,
Critical care,
University School,
Associate,
The Conference Board,
JD,
Corporate development,
Growth,
Customer service,
New York University School of Law,
Clinical trial,
Marketing,
High,
ERT,
Management,
Deutsch,
Clario Tech BOSTON, March 15, 2023 /PRNewswire-PRWeb/ -- uMotif – one of the clinical trial technology market's fastest growing companies – bolstered its status as the leader in next-generation eCOA/ePRO with the announcement that life science and healthcare executive Adam Deutsch has joined its Board of Directors.
Key Points:
- In bringing strong business acumen and a thoughtful approach to transforming companies, Deutsch is focused on how to better serve the research participant.
- uMotif CEO Steve Rosenberg ( LinkedIn ) said, "Adam has an impeccable track record of guiding the growth of private and public companies in our industry.
- uMotif Chairman of the Board Steve Powell ( LinkedIn ) said, "we're delighted to welcome Adam Deutsch to the uMotif Board.
- His expertise in creating healthcare and life science market leaders will greatly benefit uMotif as it pursues its ambitious growth plans.
Retrieved on:
Tuesday, February 14, 2023
ChromeOS,
Best in Show (film),
Patient,
Language,
Motif,
Clinical trial,
Research,
IOS,
RWE,
Android,
Medical imaging,
Medical device BOSTON, Feb. 14, 2023 /PRNewswire-PRWeb/ -- uMotif, one of the clinical trial technology market's fastest growing companies, was awarded Best of Show for its groundbreaking Motif data capture interface by attendees of the SCOPE Summit for Clinical Ops Executives in Orlando last week.
Key Points:
- Each petal represents a different question, such as an Outcome Measure, symptom, or eDiary entry.
- The highly visual and easy-to-use interface is fast and engaging, which leads to higher rates of data capture compliance.
- The Motif was independently validated by SAFIRA Clinical Research as the first new alternative to text-based instruments for clinical, post-marketing and real-world research since paper instruments were deployed on smartphones.
- When patients stay engaged, sponsors and CROs capture more and better-quality data, so they can speed the delivery of new medicines to people who are waiting."
